within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EE51_LatanoprostAndNetarsudil;

model LatanoprostAndNetarsudil
  extends Pharmacolibrary.Drugs.ATC.S.S01EE51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01EE51</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Latanoprost and netarsudil is a fixed-dose combination ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprost is a prostaglandin F2Î± analogue increasing uveoscleral outflow, while netarsudil is a Rho kinase inhibitor that reduces intraocular pressure by increasing trabecular outflow and decreasing episcleral venous pressure. The combination is approved and marketed under brand names such as Rocklatan or Roclanda.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters have been reported in the literature for the fixed combination of latanoprost and netarsudil (S01EE51) in humans. Individual drug PK data exist but not for the combination product.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LatanoprostAndNetarsudil;
